Rimegepant: Safe Daily Migraine Prevention, New Study Finds

Research Summary

A recent study published in the Journal of Headache and Pain assessed the safety of daily 75 mg rimegepant for preventing episodic migraines over 24 weeks. The study involved 250 adults, predominantly female (82%) and White (86%), with an average age of 43 years. While the study didn't evaluate efficacy, it found that 54% experienced at least one adverse event, with nasopharyngitis (9%), COVID-19 (6%), and nausea (6%) being the most common. Importantly, no serious adverse events occurred, and only 3% discontinued rimegepant due to adverse effects. The study concluded that rimegepant has a favorable safety profile for migraine prevention.

Study Details

📄 Title: A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75 mg rimegepant for episodic migraine prevention.

👥 Research Team: Antinew J et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Dec 9

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.